anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Galantamine
Trial phase: Not Applicable
ATC code: N06DA04
SMILES: [H][C@]12C[C@@H](O)C=C[C@]13CCN(C)Cc1ccc(OC)c(c13)O2
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 34
Group description: Galantamine 8 mg/day given for 10 days.
Eligibility criteria:
Inclusion Criteria:

Male and females, between the ages 21 and 50
Fulfill criteria for past cocaine dependence
No cocaine use for the past 30 days
No other current dependence or abuse of other drugs or alcohol
No current medical problems and normal ECG
Not pregnant,nor breast feeding,
Using acceptable birth control methods.

Exclusion Criteria:

Current major psychiatric illness including mood, psychotic or anxiety disorders
History of major medical illnesses; including asthma or chronic obstructive lung disease, history or current gastrointestinal ulcer, hepatic or renal impairment and cardiac rhythm disturbances
Use of other medications including,drugs that slow heart rate
Known allergy to galantamine
Intervention: Fluoxetine
Trial phase: Not Applicable
ATC code: N06AB03 | N06CA03
SMILES: CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 69
Group description: Participants received antidepressant treatment with fluoxetine for 30 weeks

Fluoxetine: Participants took 10 to 40 mg per day of fluoxetine for 30 weeks.

N=69
Eligibility criteria:
Inclusion Criteria:

Primary diagnosis of nonpsychotic MDD (single or recurrent) for at least 4 weeks before study entry
In good general medical health
Normal intelligence

Exclusion Criteria:

Lifetime history of any psychotic disorder, including psychotic depression
Lifetime history of bipolar I and II disorders
Alcohol or substance dependence within the 6 months before study entry
Anorexia nervosa or bulimia within the 6 months before study entry
Pregnant or breastfeeding females, or sexually active females not using medically acceptable means of birth control (e.g., IUD, birth control pills, barrier devices)
Chronic medical illness (medically unstable and requires regular medication that may interfere with treatment interventions)
Concurrent medication(s) with psychotropic effects (e.g., anticonvulsants, steroids, etc.) other than stable ADHD medication
First degree relatives with bipolar I disorder
Severe suicidal ideation or previous history of serious suicide attempt within this episode
Prior failure to respond to an adequate treatment with fluoxetine (defined as at least 40 mg/day for 4 weeks)
Non-English speaking
Intervention: Nuvaring
Trial phase: Not Applicable
SMILES: C#CC1(O)CCC2C3CCC4=CC(=O)CCC4C3C(=C)CC21CC.C#CC1(O)CCC2C3CCc4cc(O)ccc4C3CCC21C
Sex: Female
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 7
Group description: intravaginal contraception
Eligibility criteria:
Inclusion Criteria:

Female
18-35 years
In general good health
With regular menses (every 28-32 days)
Seeking contraception and willing to use a hormonal method for at least 6 months

Exclusion Criteria:

Current or recent (within the past 8 weeks) vaginitis or pelvic inflammatory disease
History of recurrent vaginitis (> 2 episodes in one year, any type)
Pregnancy
Recent use of hormonal contraceptives
Depot medroxyprogesterone: 6 months
Progestin implants: 3 months
Oral contraceptives: 3 months
Hormone impregnated IUD: 3 months
Contraindications to use of oral contraceptive pills or vaginal ring
History of deep vein thrombosis
Known coagulopathy or thrombophilia
Unexplained vaginal bleeding
Uncontrolled hypertension
Diabetes with vascular changes
Present or history of hepatic disease or liver tumors
Migraines with neurologic changes
Myocardial infection
Pulmonary embolus
Stroke
Breast cancer
Hypersensitivity or allergy to hormonal contraception
Heavy Smoking ( ≥ 15 cigarettes per day)
Intervention: Acetaminophen
Trial phase: Phase 4
ATC code: N02AJ01 | N02AJ06 | N02AJ13 | N02AJ17 | N02BE01 | N02BE51 | N02BE71
SMILES: CC(=O)Nc1ccc(O)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 27
Group description: all subjects receive 4 g/day of acetaminophen for 10 consecutive days in this open-label study
Eligibility criteria:
Inclusion Criteria:

age 21 years or older
provide written informed consent
consume, on average, less than 1 alcoholic beverage daily for the previous 3 months and would be considered non-drinkers

Exclusion Criteria:

History of ingesting more than 4 grams of acetaminophen per day for any of the 4 days preceding study enrollment
Currently taking isoniazid
Consumption of any alcoholic beverage during the run-in period
A detectable serum acetaminophen at baseline
Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels greater than 50 IU/L at the start of the run-in period or at baseline
Platelet count less than 125,000/cc at baseline
Positive pregnancy test at baseline (female participants only)
Currently adheres to a fasting type diet as determined by self report
Currently has anorexia nervosa as determined by self report
Subject appears clinically intoxicated, psychiatrically impaired or unable to give informed consent for any reason
Known hypersensitivity to acetaminophen
Intervention: Metformin
Trial phase: Phase 2
ATC code: A10BA02 | A10BD02 | A10BD03 | A10BD05 | A10BD07 | A10BD08 | A10BD10 | A10BD11 | A10BD13 | A10BD14 | A10BD15 | A10BD16 | A10BD17 | A10BD18 | A10BD20 | A10BD22 | A10BD23 | A10BD25 | A10BD26 | A10BD27
SMILES: CN(C)C(=N)NC(=N)N
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 5
Group description: metformin in doses from 250mg to 2000mg/day for 26 weeks
Eligibility criteria:
Inclusion Criteria:

Subjects will be between the ages of 10 and 17, male or female, any race or ethnicity
Any SPMI pediatric diagnosis that meets DSM-IV criteria and frequently is treated with a SGA- typically but not limited to psychotic, mood, pervasive developmental, oppositional defiant, and conduct disorders
SGA-naïve or less than 2 weeks exposure to any SGA, except ziprasidone
Legal guardian able and willing to give written informed consent
If competent, subject able and willing to assent for their own participation

Exclusion Criteria:

Previous trial of metformin
Recommendation for treatment with clozapine or ziprasidone
Current use of insulin or any oral hypoglycemic agent
Current use of a medication known to mitigate weight gain - amantidine, histamine (H2) antagonists (cimetidine, ranitidine, nizatidine), topiramate, orlistat, sibutramine, stimulants (dextroamphetamine, methylphenidate)
Any current or past diagnosis of an eating disorder
Diabetes mellitus
Current active thyroid (TSH >18 microIU/ml; T4 total >18 mcg/dl), hepatic (2 LFTs >4x upper limits of normal), renal (serum Creatinine >1.4 mg/dL in females and serum Creatinine >1.5 mg/dL in males), cardiac, gastrointestinal, or adrenal disease
Current substance abuse/dependence within past 2 weeks; a positive urine tox screen at baseline in the absence of meeting criteria for abuse/dependence will not preclude enrollment.
Pregnancy or breast feeding
Intervention: Technetium (99mTc) sestamibi
Trial phase: Not Applicable
SMILES: [C-]#[N+]CC(C)(C)OC.[C-]#[N+]CC(C)(C)OC.[C-]#[N+]CC(C)(C)OC.[C-]#[N+]CC(C)(C)OC.[C-]#[N+]CC(C)(C)OC.[C-]#[N+]CC(C)(C)OC.[Tc]
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 969
Group description: Participants underwent conventional mammography and molecular breast imaging after a 740-millibecquerel (mBQ)(20-mCi) Technetium (99mTc) sestamibi injection.
Eligibility criteria:
Inclusion Criteria:

Past prior screening mammography (SM) interpreted as negative or benign (This screening must have been performed at Mayo Clinic Rochester, Minnesota).
Past prior SM interpreted as heterogeneously dense or extremely dense (This screening must have been performed at Mayo Clinic Rochester, Minnesota).
Women younger than 50 years who had not undergone prior mammography, as most of these women have dense breasts.

Subjects had to have at least one of the following risk factors:

Known mutation in breast cancer susceptibility gene 1 (BRCA1) or breast cancer susceptibility gene 2 (BRCA2)
History of chest, mediastinal, or axillary irradiation
Personal history of breast cancer
History of prior biopsy showing atypical ductal hyperplasia, atypical lobular hyperplasia, lobular carcinoma in situ, or atypical papilloma
Gail or Claus model lifetime risk greater than or equal to 20%
Gail model 5 year risk greater or equal to 2.5%
Gail model 5 year risk greater or equal to 1.6%
One first-degree relative with history of breast cancer
Two second-degree relatives with history of breast cancer

Exclusion Criteria:

They are unable to understand and sign the consent form
They are pregnant or lactating
They are physically unable to sit upright and still for 40 minutes.
They have self-reported signs or symptoms of breast cancer (palpable mass, bloody nipple discharge, axillary mass etc.).
They have had needle biopsy within 3 months, or breast surgery within 1 year prior to the study.
They are currently taking tamoxifen, evista (raloxifene), or an aromatase inhibitor for adjuvant therapy or chemoprevention.
Intervention: RIFAMPIN
Trial phase: Phase 1
ATC code: J04AB02 | J04AM02 | J04AM05 | J04AM06 | J04AM07 | J04BA50 | J04BA51
SMILES: COC1C=COC2(C)Oc3c(C)c(O)c4c(O)c(c(C=NN5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)C(C)=CC=CC(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C1C
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 29
Group description: Randomized, crossover trial. 1: Rifampicin (300 mg/d) given alone for 7 days; 2: daily combination with 450 μmol SFN (Broccoli Sprout extract); 3: SFN alone. 29 participants consented. The powdered broccoli extract imparted a bitter taste to the cheese soup used as vehicle. We had all potential participants try the soup before committing to participate. 3 participants who initially did not object to the taste did dropout and did not finish any of the study arms due to dislike or intolerance of the extract. Two of these participants became nauseated, one also had vomiting but it was determined that the subject was suffering from the flu and thus the response was deemed by our attending physician not to be solely treatment related. Three additional participants did not complete all their study periods (one developed apparent lactose intolerance to the soup, one did not routinely comply with study activities, and one relocated out of state after the second study period).
Eligibility criteria:
Inclusion Criteria:

Adults from all ethnicities will be encouraged to participate, with our recruitment efforts we expect similar profile as that of the greater Seattle area.

Exclusion Criteria:

Exclusion criteria address a mix of medical and practical issues and include:

Medical history of gastrointestinal, hepatic, or renal disorders
Pregnancy or lactation
Known allergies/intolerances to any foods used in the feeding trial
Weight loss or gain greater than 4.5 kg within the past year
Major changes in eating habits within the past year (e.g. adoption of a faddish diet)
Antibiotic use within the past 3 months
Body weight greater than 150% of desirable
Exercise patterns that require or result in major changes in diet
Current use of prescription medication (including oral contraceptives)
Current use of over-the-counter medications and herbal supplements
Regular exposure to passive smoke
Occupational exposure to smoke or organic solvents
Food dislikes that would preclude participation in the feeding trial
Alcohol intake of greater than 2 drinks/day (2 drinks=720 mL beer, 240 mL wine, or 9 mL spirits). Additionally, before the trial, participants will have a blood draw to be sent to the UW Medical Center Lab for liver and kidney functions profile and pregnancy test for women. Those with abnormal test results will be excluded as well as pregnant women.
Intervention: Perflutren
Trial phase: Phase 4
SMILES: FC(F)(F)C(F)(F)C(F)(F)F
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 1053
Group description: Patients who had undergone unenhanced echocardiography yielding suboptimal images and who were determined by the Principal Investigator to require DEFINITY-enhanced echocardiography
Eligibility criteria:
Inclusion criteria

Patients who, in the investigator's opinion, require DEFINITY® echocardiography due to suboptimal, unenhanced images.

Exclusion criteria

Known hypersensitivity to perflutren, DEFINITY®, or other echo contrast agent.
Prior SAE associated with perflutren, DEFINITY®, or administration of other echo contrast agent.
Intervention: 2-(4-Chloro-3-(3-(1-hydroxycycloheptyl)propanoyl)phenyl)-4-((2R)-2-hydroxy-3-methoxy-propyl)-1,2,4-triazine-3,5-dione
Trial phase: Phase 2
SMILES: COCC(O)Cn1c(=O)cnn(-c2ccc(Cl)c(C(=O)NCC3(O)CCCCCC3)c2)c1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 53
Group description: CE-224,535 500 milligram (mg) tablet orally twice daily for 12 weeks.
Eligibility criteria:
Inclusion Criteria:

Active rheumatoid arthritis
Incomplete response to methotrexate

Exclusion Criteria:

Must not be on biologic therapies
No recent infections
Intervention: Sulfasalazine
Trial phase: Phase 4
ATC code: A07EC01 | G01AE10
SMILES: O=C(O)c1cc(/N=N/c2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 2
Group description: All participants received sulfasalazine 30-50 milligrams (mg)/kilograms (kg)/day, divided into twice daily (BID) doses, for 6 days. On Day 7, the morning dose was administered at the site in presence of site staff. Sulfasalazine was administered orally in the form of 500-mg tablets.
Eligibility criteria:
Inclusion Criteria:

Patients with a diagnosis of oligoarticular, polyarticular, psoriatic or enthesitis-related JIA as determined by ILAR criteria. Patients who have been continuously treated with generic sulfasalazine delayed release formulation and have tolerated the product for at least 3 months prior to study enrolment and who are switched to Azulfidine-EN at least 8 days prior to Day 0 are eligible.
Patients must be at least 6 years of age and has not reached his/her 18th birthday prior to the Baseline Visit (Day 0).
Onset of JIA must have occurred prior to the patient's 16th birthday.
Patients must weigh at least 20 kg.
Patients must be on sulfasalazine 500 mg delayed release tablets and the total daily dose must be within the specified range of 30-60 mg/kg/day with a maximum daily dose of 3 g/day

Exclusion Criteria:

Patient currently with systemic features of systemic JIA.
Hypersensitivity to sulfasalazine , its metabolites, sulfonamides or salicylates.
History of sensitivity to heparin or heparin-induced thrombocytopenia.
Inability to swallow whole (uncrushed) sulfasalazine 500 mg delayed release tablets as required by protocol
Intervention: Riboflavin
Trial phase: Phase 3
ATC code: A11HA04 | S01XA26
SMILES: Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 74
Group description: riboflavin ophthalmic solution without UVA irradiation
Eligibility criteria:
Inclusion Criteria:

Diagnosis of keratoconus
Documented progression over previous 24 months
Decreased BSCVA
Must complete all study visits

Exclusion Criteria:

Prior corneal surgery or Intacs
History of delayed wound healing
Intervention: Canagliflozin
Trial phase: Phase 2
ATC code: A10BD16 | A10BK02
SMILES: [H][C@@]1(c2ccc(C)c(Cc3ccc(-c4ccc(F)cc4)s3)c2)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 98
Group description: Each patient received 50 mg of canagliflozin (JNJ-28431754) once daily for 12 weeks.
Eligibility criteria:
Inclusion Criteria:

BMI >=30 kg/m2 and <50 kg/m2 or a BMI >=27 kg/m2 and <50 kg/m2 in the presence of controlled hypertension and/or treated or untreated dyslipidemia
Must have a stable weight, i.e., increasing or decreasing not more than 5% in the 3 months before screening
Serum creatinine <=1.5 mg/dL for men and <=1.4 mg/dL for women at screening
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels within 2 times the upper limit of normal (ULN) and bilirubin within the normal range, unless the findings are consistent with Gilbert's disease
fasting plasma glucose PG <7.0 mmol/L (126 mg/dL) at screening

Exclusion Criteria:

A history of hereditary glucose-galactose malabsorption or primary renal glycosuria
An established diagnosis of diabetes mellitus or treatment with glucose lowering drugs at screening
A history of reactive hypoglycemia or of symptomatology possibly due to hypoglycemia
Fasting triglyceride level >6.78 mmol/L (600 mg/dL) at screening
History of obesity with a known cause (e.g., Cushing's disease)
Intervention: Canagliflozin
Trial phase: Phase 2
ATC code: A10BD16 | A10BK02
SMILES: [H][C@@]1(c2ccc(C)c(Cc3ccc(-c4ccc(F)cc4)s3)c2)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 93
Group description: Each patient received 100 mg of canagliflozin (JNJ-28431754) once daily for 12 weeks.
Eligibility criteria:
Inclusion Criteria:

BMI >=30 kg/m2 and <50 kg/m2 or a BMI >=27 kg/m2 and <50 kg/m2 in the presence of controlled hypertension and/or treated or untreated dyslipidemia
Must have a stable weight, i.e., increasing or decreasing not more than 5% in the 3 months before screening
Serum creatinine <=1.5 mg/dL for men and <=1.4 mg/dL for women at screening
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels within 2 times the upper limit of normal (ULN) and bilirubin within the normal range, unless the findings are consistent with Gilbert's disease
fasting plasma glucose PG <7.0 mmol/L (126 mg/dL) at screening

Exclusion Criteria:

A history of hereditary glucose-galactose malabsorption or primary renal glycosuria
An established diagnosis of diabetes mellitus or treatment with glucose lowering drugs at screening
A history of reactive hypoglycemia or of symptomatology possibly due to hypoglycemia
Fasting triglyceride level >6.78 mmol/L (600 mg/dL) at screening
History of obesity with a known cause (e.g., Cushing's disease)
Intervention: Canagliflozin
Trial phase: Phase 2
ATC code: A10BD16 | A10BK02
SMILES: [H][C@@]1(c2ccc(C)c(Cc3ccc(-c4ccc(F)cc4)s3)c2)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 96
Group description: Each patient received 300 mg of canagliflozin (JNJ-28431754) once daily for 12 weeks.
Eligibility criteria:
Inclusion Criteria:

BMI >=30 kg/m2 and <50 kg/m2 or a BMI >=27 kg/m2 and <50 kg/m2 in the presence of controlled hypertension and/or treated or untreated dyslipidemia
Must have a stable weight, i.e., increasing or decreasing not more than 5% in the 3 months before screening
Serum creatinine <=1.5 mg/dL for men and <=1.4 mg/dL for women at screening
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels within 2 times the upper limit of normal (ULN) and bilirubin within the normal range, unless the findings are consistent with Gilbert's disease
fasting plasma glucose PG <7.0 mmol/L (126 mg/dL) at screening

Exclusion Criteria:

A history of hereditary glucose-galactose malabsorption or primary renal glycosuria
An established diagnosis of diabetes mellitus or treatment with glucose lowering drugs at screening
A history of reactive hypoglycemia or of symptomatology possibly due to hypoglycemia
Fasting triglyceride level >6.78 mmol/L (600 mg/dL) at screening
History of obesity with a known cause (e.g., Cushing's disease)
Intervention: Nepadutant
Trial phase: Phase 1
SMILES: CC(=O)NC1C(NC(=O)CC2NC(=O)C(CC(C)C)NC(=O)C3CNC(=O)CC(NC2=O)C(=O)NC(Cc2c[nH]c4ccccc24)C(=O)NC(Cc2ccccc2)C(=O)N3)OC(CO)C(O)C1O
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 12
Group description: Nepadutant 0.1 mg/kg
Eligibility criteria:
Inclusion Criteria:

Subjects will be eligible for inclusion in the study if they meet all of the following criteria:

Infants with a history consistent with a diagnosis of colic or other functional gastrointestinal disorders
Age >6 weeks and < 24 weeks
At least 44 weeks post-conceptual age at enrolment
Normal growth
Informed consent by parents (one or both) or legal guardian
Caregiver available to be trained in collection and storage of used diapers
Caregiver available to record feeding episodes and defecations on the diary

Exclusion Criteria:

Subjects will be excluded from the study if they meet any of the following criteria:

Clinical evidence of major cardiovascular, respiratory, renal, hepatic, endocrine, metabolic, gastrointestinal (excluding infantile colic and other functional gastrointestinal disorders, unless associated to symptoms which are likely to interfere with drug absorption, e.g. frequent vomiting), haematological, severe dermatological or neurological pathology or other diseases;
Previous major surgery or blood loss
Intake of antimuscarinic drugs, simethicone, or dimethicone 24 hours before study treatment administration.
Intervention: Nepadutant
Trial phase: Phase 1
SMILES: CC(=O)NC1C(NC(=O)CC2NC(=O)C(CC(C)C)NC(=O)C3CNC(=O)CC(NC2=O)C(=O)NC(Cc2c[nH]c4ccccc24)C(=O)NC(Cc2ccccc2)C(=O)N3)OC(CO)C(O)C1O
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 8
Group description: Nepadutant 0.5 mg/kg
Eligibility criteria:
Inclusion Criteria:

Subjects will be eligible for inclusion in the study if they meet all of the following criteria:

Infants with a history consistent with a diagnosis of colic or other functional gastrointestinal disorders
Age >6 weeks and < 24 weeks
At least 44 weeks post-conceptual age at enrolment
Normal growth
Informed consent by parents (one or both) or legal guardian
Caregiver available to be trained in collection and storage of used diapers
Caregiver available to record feeding episodes and defecations on the diary

Exclusion Criteria:

Subjects will be excluded from the study if they meet any of the following criteria:

Clinical evidence of major cardiovascular, respiratory, renal, hepatic, endocrine, metabolic, gastrointestinal (excluding infantile colic and other functional gastrointestinal disorders, unless associated to symptoms which are likely to interfere with drug absorption, e.g. frequent vomiting), haematological, severe dermatological or neurological pathology or other diseases;
Previous major surgery or blood loss
Intake of antimuscarinic drugs, simethicone, or dimethicone 24 hours before study treatment administration.
Intervention: Dalcetrapib
Trial phase: Phase 2
SMILES: CCC(CC)CC1(C(=O)Nc2ccccc2SC(=O)C(C)C)CCCCC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 64
Group description: Dalcetrapib (RO4607381): 600mg po daily for 24 months
Eligibility criteria:
Inclusion Criteria:

adult patients, 18-75 years of age;
CHD, including patients with other CHD risk factors;
treated appropriately for dyslipidemia;
clinically stable.

Exclusion Criteria:

previous exposure to any cholesteryl ester transfer protein (CETP) inhibitor or vaccine;
recent (within 3 months) clinically significant coronary events, transient ischemic attacks or cerebrovascular accident;
severe anemia;
uncontrolled hypertension;
poorly controlled diabetes.
Intervention: Dalcetrapib
Trial phase: Phase 2
SMILES: CCC(CC)CC1(C(=O)Nc2ccccc2SC(=O)C(C)C)CCCCC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 236
Group description: dalcetrapib: 600mg po daily for 36 weeks
Eligibility criteria:
Inclusion Criteria:

adult patients, 18-75 years of age;
CHD or CHD risk equivalent;
appropriately treated for accepted LDL-C level.

Exclusion Criteria:

treatment with drugs raising HDL-C (eg niacin, fibrates);
uncontrolled hypertension;
recent (within 3 months) clinically significant coronary events, transient ischemic attacks or cerebrovascular accident;
severe anemia;
poorly controlled diabetes.